Microcap Ledger Tonix Pharmaceuticals Holding Corp. $TNXP
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Berkeley Heights, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 17,151,024 [10-Q 2026-08-10]
What the company doesAI summary of filing
Tonix Pharmaceuticals is a biopharmaceutical company that commercializes and develops therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. The company is a revenue-generating, clinical-stage developer with one FDA-approved marketed product: TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia in adults, launched in November 2025, along with two acquired migraine products, Zembrace SymTouch and Tosymra. The company generates revenue from sales of these products through its internal sales force and contracted distribution channels. Tonix also maintains a development pipeline of clinical and preclinical-stage programs, including TNX-102 SL for major depressive disorder and acute stress disorder, TNX-4800 for Lyme disease prevention, TNX-1500 for kidney transplant rejection, and several other candidates in earlier stages. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $20.42M | −$80.75M | −$84.56M | $176.23M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $13.11M | −$124.02M | −$99.84M | $207.64M | [10-K 2026-03-12] |
| FY ended Dec 2024 | $10.09M | −$130.04M | −$60.92M | $98.78M | [10-K 2026-03-12] |
- Quarterly cash burn
- −$42.28M
- Cash runway Estimate
- ~12.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 186,894,225 | [10-Q 2024-11-12] |
| 2025-03-17 | 6,434,881 | [10-K 2025-03-18] |
| 2025-05-12 | 7,324,670 | [10-Q 2025-05-12] |
| 2025-08-11 | 8,765,896 | [10-Q 2025-08-11] |
| 2025-11-10 | 11,776,542 | [10-Q 2025-11-10] |
| 2026-03-11 | 13,405,401 | [10-K 2026-03-12] |
| 2026-05-08 | 15,940,801 | [10-Q 2026-05-11] |
| 2026-08-07 | 17,151,024 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2025-06-12; declared effective 2025-09-04 [S-3 2025-06-12]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-27 | Lederman Seth | buy | 2,000 | $13.79 | [4 2026-08-31] |
| 2026-08-20 | Bagger Richard H | buy | 1,000 | $12.60 | [4 2026-08-24] |
| 2026-06-30 | Saenger Bradley | other | 1,453 | $10.91 | [4 2026-07-09] |
| 2026-06-12 | Taylor Carolyn E. | buy | 1,415 | $10.55 | [4 2026-06-15] |
| 2026-06-09 | Lederman Seth | buy | 5,000 | $11.79 | [4 2026-06-09] |
| 2026-06-08 | Stillwell Richard Newcomb | buy | 5,000 | $11.65 | [4 2026-06-09] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-02 | 8-K | Other events |
| 2026-09-22 | 8-K | Other events |
| 2026-09-08 | 8-K | Other events |
| 2026-08-18 | 8-K | Director or officer change; Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-08-03 | 8-K | Regulation FD disclosure; Other events |
| 2026-07-21 | 8-K | Director or officer change |
| 2026-07-13 | 8-K | Regulation FD disclosure; Other events |
| 2026-06-29 | 8-K | Regulation FD disclosure; Other events |
Alerts for $TNXP
Email me when Tonix Pharmaceuticals Holding Corp. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.